240 related articles for article (PubMed ID: 30301828)
1. Telomerase Activation and ATRX Mutations Are Independent Risk Factors for Metastatic Pheochromocytoma and Paraganglioma.
Job S; Draskovic I; Burnichon N; Buffet A; Cros J; Lépine C; Venisse A; Robidel E; Verkarre V; Meatchi T; Sibony M; Amar L; Bertherat J; de Reyniès A; Londoño-Vallejo A; Favier J; Castro-Vega LJ; Gimenez-Roqueplo AP
Clin Cancer Res; 2019 Jan; 25(2):760-770. PubMed ID: 30301828
[TBL] [Abstract][Full Text] [Related]
2. Molecular evaluation of a sporadic paraganglioma with concurrent IDH1 and ATRX mutations.
Zhang J; Jiang J; Luo Y; Li X; Lu Z; Liu Y; Huang J; Hou Y; Pang Y; Sun MYF; Wang TS; Evans DB; Pacak K; Zhuang Z; Gao X
Endocrine; 2018 Aug; 61(2):216-223. PubMed ID: 29846902
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations.
Bernardo-Castiñeira C; Valdés N; Celada L; Martinez ASJ; Sáenz-de-Santa-María I; Bayón GF; Fernández AF; Sierra MI; Fraga MF; Astudillo A; Jiménez-Fonseca P; Rial JC; Hevia MÁ; Turienzo E; Bernardo C; Forga L; Tena I; Molina-Garrido MJ; Cacho L; Villabona C; Serrano T; Scola B; Chirivella I; Del Olmo M; Menéndez CL; Navarro E; Tous M; Vallejo A; Athimulam S; Bancos I; Suarez C; Chiara MD
J Clin Endocrinol Metab; 2019 Nov; 104(11):5673-5692. PubMed ID: 31216007
[TBL] [Abstract][Full Text] [Related]
4. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
[TBL] [Abstract][Full Text] [Related]
5. Telomere elongation via alternative lengthening of telomeres (ALT) and telomerase activation in primary metastatic medulloblastoma of childhood.
Minasi S; Baldi C; Pietsch T; Donofrio V; Pollo B; Antonelli M; Massimino M; Giangaspero F; Buttarelli FR
J Neurooncol; 2019 May; 142(3):435-444. PubMed ID: 30830680
[TBL] [Abstract][Full Text] [Related]
6. Transcriptome Analysis of lncRNAs in Pheochromocytomas and Paragangliomas.
Job S; Georges A; Burnichon N; Buffet A; Amar L; Bertherat J; Bouatia-Naji N; de Reyniès A; Drui D; Lussey-Lepoutre C; Favier J; Gimenez-Roqueplo AP; Castro-Vega LJ
J Clin Endocrinol Metab; 2020 Mar; 105(3):. PubMed ID: 31678991
[TBL] [Abstract][Full Text] [Related]
7.
Dwight T; Flynn A; Amarasinghe K; Benn DE; Lupat R; Li J; Cameron DL; Hogg A; Balachander S; Candiloro ILM; Wong SQ; Robinson BG; Papenfuss AT; Gill AJ; Dobrovic A; Hicks RJ; Clifton-Bligh RJ; Tothill RW
Endocr Relat Cancer; 2018 Jan; 25(1):1-9. PubMed ID: 28974544
[TBL] [Abstract][Full Text] [Related]
8. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
9. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas.
Fishbein L; Khare S; Wubbenhorst B; DeSloover D; D'Andrea K; Merrill S; Cho NW; Greenberg RA; Else T; Montone K; LiVolsi V; Fraker D; Daber R; Cohen DL; Nathanson KL
Nat Commun; 2015 Jan; 6():6140. PubMed ID: 25608029
[TBL] [Abstract][Full Text] [Related]
10. Epithelial to mesenchymal transition is activated in metastatic pheochromocytomas and paragangliomas caused by SDHB gene mutations.
Loriot C; Burnichon N; Gadessaud N; Vescovo L; Amar L; Libé R; Bertherat J; Plouin PF; Jeunemaitre X; Gimenez-Roqueplo AP; Favier J
J Clin Endocrinol Metab; 2012 Jun; 97(6):E954-62. PubMed ID: 22492777
[TBL] [Abstract][Full Text] [Related]
11. Metastatic Pheochromocytoma and Paraganglioma: Somatostatin Receptor 2 Expression, Genetics, and Therapeutic Responses.
Fischer A; Kloos S; Maccio U; Friemel J; Remde H; Fassnacht M; Pamporaki C; Eisenhofer G; Timmers HJLM; Robledo M; Fliedner SMJ; Wang K; Maurer J; Reul A; Zitzmann K; Bechmann N; Žygienė G; Richter S; Hantel C; Vetter D; Lehmann K; Mohr H; Pellegata NS; Ullrich M; Pietzsch J; Ziegler CG; Bornstein SR; Kroiss M; Reincke M; Pacak K; Grossman AB; Beuschlein F; Nölting S
J Clin Endocrinol Metab; 2023 Sep; 108(10):2676-2685. PubMed ID: 36946182
[TBL] [Abstract][Full Text] [Related]
12. Acquired hypermethylation of the P16INK4A promoter in abdominal paraganglioma: relation to adverse tumor phenotype and predisposing mutation.
Kiss NB; Muth A; Andreasson A; Juhlin CC; Geli J; Bäckdahl M; Höög A; Wängberg B; Nilsson O; Ahlman H; Larsson C
Endocr Relat Cancer; 2013 Feb; 20(1):65-78. PubMed ID: 23154831
[TBL] [Abstract][Full Text] [Related]
13. LncRNA expression and SDHB mutations in pheochromocytomas and paragangliomas.
Li H; Hardin H; Zaeem M; Huang W; Hu R; Lloyd RV
Ann Diagn Pathol; 2021 Dec; 55():151801. PubMed ID: 34461576
[TBL] [Abstract][Full Text] [Related]
14. Malignant Intrarenal/Renal Pelvis Paraganglioma with Co-Occurring SDHB and ATRX Mutations.
Irwin T; Konnick EQ; Tretiakova MS
Endocr Pathol; 2019 Dec; 30(4):270-275. PubMed ID: 31705439
[TBL] [Abstract][Full Text] [Related]
15. Targeting NAD
Pang Y; Lu Y; Caisova V; Liu Y; Bullova P; Huynh TT; Zhou Y; Yu D; Frysak Z; Hartmann I; Taïeb D; Pacak K; Yang C
Clin Cancer Res; 2018 Jul; 24(14):3423-3432. PubMed ID: 29636359
[No Abstract] [Full Text] [Related]
16. Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma.
Koneru B; Lopez G; Farooqi A; Conkrite KL; Nguyen TH; Macha SJ; Modi A; Rokita JL; Urias E; Hindle A; Davidson H; Mccoy K; Nance J; Yazdani V; Irwin MS; Yang S; Wheeler DA; Maris JM; Diskin SJ; Reynolds CP
Cancer Res; 2020 Jun; 80(12):2663-2675. PubMed ID: 32291317
[TBL] [Abstract][Full Text] [Related]
17. Functional Loss of
Graham MK; Kim J; Da J; Brosnan-Cashman JA; Rizzo A; Baena Del Valle JA; Chia L; Rubenstein M; Davis C; Zheng Q; Cope L; Considine M; Haffner MC; De Marzo AM; Meeker AK; Heaphy CM
Mol Cancer Res; 2019 Dec; 17(12):2480-2491. PubMed ID: 31611308
[TBL] [Abstract][Full Text] [Related]
18. Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma.
Murakami M; Sun N; Greunke C; Feuchtinger A; Kircher S; Deutschbein T; Papathomas T; Bechmann N; William Wallace P; Peitzsch M; Korpershoek E; Friemel J; Gimenez-Roqueplo AP; Robledo M; J L M Timmers H; Canu L; Weber A; R de Krijger R; Fassnacht M; Knösel T; Kirchner T; Reincke M; Karl Walch A; Kroiss M; Beuschlein F
Eur J Endocrinol; 2021 Jun; 185(1):179-191. PubMed ID: 33983135
[TBL] [Abstract][Full Text] [Related]
19. Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.
Alzoubi H; Minasi S; Gianno F; Antonelli M; Belardinilli F; Giangaspero F; Jaffrain-Rea ML; Buttarelli FR
Endocr Pathol; 2022 Dec; 33(4):494-505. PubMed ID: 34993885
[TBL] [Abstract][Full Text] [Related]
20. SDHB mutation status and tumor size but not tumor grade are important predictors of clinical outcome in pheochromocytoma and abdominal paraganglioma.
Assadipour Y; Sadowski SM; Alimchandani M; Quezado M; Steinberg SM; Nilubol N; Patel D; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):230-239. PubMed ID: 27839933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
